CAR T-cell Therapy Safe, Effective in Treatment-resistant Myeloma: Study
A CAR T-cell therapy called CART-ddBCMA that targets the protein BCMA — produced at high levels in myeloma cells — safely led to lasting…
Steve Bryson, PhD, science writer—
Articles by Steve Bryson
Ninlaro as Oral Combo Therapy Fails at Trial in Heavily Treated Patients
Adding Ninlaro (ixazomib) to cyclophosphamide and dexamethasone does not improve progression-free survival for multiple myeloma patients who relapsed after several lines of treatment,…
Europe’s CHMP Supports Carvykti T-cell Therapy Approval in EU
Carvykti (ciltacabtagene autoleucel; cilta-cel) has been recommended for approval in Europe by the Committee for Medicinal Products for Human Use (CHMP), an arm of the…
Longer Survival for Black vs White Myeloma Patients With Same Care
Black people with multiple myeloma live longer than white patients with similar disease symptoms when both receive the same new and updated medical treatments,…
Sarclisa Extends Survival in RRMM, Long-term Phase 3 Trial Data Shows
The therapy Sarclisa (isatuximab) extended survival by nearly seven months in relapsed/refractory multiple myeloma patients also given Pomalyst (pomalidomide) and dexamethasone as standard…
FDA Approves 8th Darzalex Faspro Indication for Myeloma Patients
The U.S. Food and Drug Administration (FDA) has approved Darzalex Faspro (daratumumab and hyaluronidase), in combination with Kyprolis (carfilzomib) and the corticosteroid dexamethasone,…
Blood Type O Lowers Myeloma Risk, But Outcomes Typically Worse
People with blood type O are significantly less likely to develop multiple myeloma, but those who do are…
China Approves Xgeva to Prevent Bone Events Due to Multiple Myeloma, Other Cancers
Xgeva (denosumab) has been approved by the China National Medical Products Administration (NMPA) to prevent…
Radiation Therapy Safe for Myeloma Patients Before CAR T-cell Infusion, Study Finds
Administering radiation therapy to people with relapsed or refractory (resistant) multiple myeloma waiting for CAR T-cells to…
Melflufen Open to Select Adults With Advanced Multiple Myeloma in US
Oncopeptides has formally opened sEAPort, its open-label expanded access program allowing adults with…
